Immunosuppressive Therapy with Everolimus Can Be Associated with Potentially Life-Threatening Lingual Angioedema
Authors:
- Uwe FuchsUFUwe Fuchs
- Armin ZittermannAZArmin Zittermann
- Heiner K. BertholdHBHeiner K. Berthold
- Gero TenderichGTGero Tenderich
- Karl W. DeyerlingKDKarl W. Deyerling
- Kazutomo MinamiKMKazutomo Minami
- Reiner KoerferRKReiner Koerfer
- 1 April 2005
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (8) , 981-983
Abstract
Everolimus has recently received approval for immunosuppressive therapy in heart transplant recipients in Austria and Germany. At our heart center we have treated 114 patients with everolimus since January 2004. Here we describe 6 cases of lingual angioedema (corresponding to 5.3% of the patients). Symptoms occurred within 2 to 41 days after initiation of therapy. In 5 out of the 6 patients, lingual angioedema disappeared with anti-allergic treatment alone. However, in one patient, two severe recurrent episodes of lingual angioedema occurred so that therapy had to be discontinued. We conclude that the potentially life-threatening condition of lingual angioedema should be considered a severe drug reaction after initiation of everolimus therapy in heart transplant recipients.Keywords
This publication has 6 references indexed in Scilit:
- Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol HistologyTransplantation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting dosesTransplantation, 2003
- Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic rangeTransplantation, 2002
- Entry‐into‐human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipientsBritish Journal of Clinical Pharmacology, 1999
- Angiotensin–converting enzyme (ACE) inhibitors and angio–oedemaBritish Journal of Dermatology, 1997